Teduglutide (GLP2 2G)
Teduglutide is a GLP-2 analogue, resistant to peptidase degradation. Enhanced biological activity relative to native GLP-2.
|Sequence (one letter code)||
|Sequence (three letter code)||
Jeppesen (2012). Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Ther. Adv. Gastroenterol., 5(3): 159. PMID: 22570676.
Schwartz et al., (2016). Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin.Transl. Gastroenterol., 7(2): e142. PMID: 26844839.
Teduglutide is a GLP-2 analogue, in which the alanine at position 2 has been substituted with glycine making the peptide resistant to degradation by dipeptidyl peptidase-4 (DPP-4); Teduglutide therefore has a longer half-life than GLP-2 (2-3 hours for teduglutide vs 7 min for GLP-2). Teduglutide has high bioavailability after subcutaneous administration, suggesting that teduglutide has enhanced biological activity, relative to native GLP-2.
GLP-2 is a gut hormone produced in the enteroendocrine L cells of gastrointestinal tract by the cleavage of the 160-amino-acid proglucagon molecule. GLP-2 is secreted following the ingestion of food and carries out its activities via the GLP-2 G-protein coupled receptors (GLP-2Rs). GLP-2 has a range of roles within the cell, including: anti-inflammatory effects; promoting the expansion of the intestinal mucosa; stimulating intestinal blood flow; inhibiting gastric acid secretion and gastric emptying; increasing intestinal barrier function and enhancing nutrient and fluid absorption.